|
Design strategies for physical-stimuli-responsive programmable nanotherapeutics
10.1016/j.drudis.2018.04.003 2018-04-10 Nanomaterials that respond to externally applied physical stimuli such as temperature, light, ultrasound, magnetic field and electric field have shown great potential for controlled and targeted delivery of therapeutic agents. However, the body of literature ... |
|
|
An operational model for GPCR homodimers and its application in the analysis of biased signaling
10.1016/j.drudis.2018.04.004 2018-04-09 G-protein-coupled receptors are one of the most important protein superfamilies as drug targets in drug discovery programs. Their interactions with ligands are influenced by their homomerization. In this study, we propose an operational model for receptor hom... |
|
|
The emerging role of copper-64 radiopharmaceuticals as cancer theranostics
10.1016/j.drudis.2018.04.002 2018-04-07 Copper radionuclides are rapidly emerging as potential diagnostic and therapeutic tools in oncology, particularly 64Cu-radiopharmaceuticals for targeting neuroendocrine, prostate, and hypoxic tumors. Unexpectedly, experimental results are also revealing the i... |
|
|
Update on the main use of biomaterials and techniques associated with tissue engineering
10.1016/j.drudis.2018.03.013 2018-03-30 Regenerative medicine involves the study of cells, signaling cues and biomatrices to restore normal function of tissues and organs. To develop the matrices for use in tissue engineering there are three main groups of biomaterials: (i) naturally derived materi... |
|
|
Extension of quality-by-design concept to the early development phase of pharmaceutical R&D processes
10.1016/j.drudis.2018.03.012 2018-03-27 Highlights • Extension of the ICH Q8 “Quality by Design (QbD)” model. • Enlarged QbD pathway for answering the challenges of drug R&D and industrial production. • Model proposal for implementation an extended QbD in the pharmaceutical preformulation study des... |
|
|
Can we accelerate medicinal chemistry by augmenting the chemist with Big Data and artificial intelligence?
10.1016/j.drudis.2018.03.011 2018-03-22 Highlights • Systematizing medicinal chemistry knowledge can make it evidence based and identify valuable exceptions to established medicinal chemistry dogma. • There is a huge amount of unique medicinal chemistry knowledge. • Evidence based medicinal chemist... |
|
|
Can hi-jacking hypoxia inhibit extracellular vesicles in cancer?
10.1016/j.drudis.2018.03.006 2018-03-22 Highlights • EVs contribute to numerous pathological problems associated with cancer. • EVs from noncancerous cells play parts in normal communication between cells. • Blocking all EV release in the body could cause as many problems as it prevents. • Hypoxia,... |
|
|
Strategic R&D transactions in personalized drug development
10.1016/j.drudis.2018.03.009 2018-03-21 Highlights • Personalized medicine is the focus of investment in start-up companies. • This trend is expected to generate more patents in the area. • Number of R＆D licenses is an indicator of the financing deals in the area. • Start-ups and their investors co... |
|
|
EU decision-making for marketing authorization of advanced therapy medicinal products: a case study
10.1016/j.drudis.2018.03.008 2018-03-21 • Relevant quality issues were raised in all assessment procedures. • Lack of efficacy and severe safety risks were decisive for non-approval. • Experimental characteristics of approved ATMPs urge stakeholders to guard patient risk. • Methodologies for develo... |
|
|
Computational modeling approaches to quantitative structure–binding kinetics relationships in drug discovery
10.1016/j.drudis.2018.03.010 2018-03-21 Highlights • The interplay of kinetic rates and binding affinity is essential in drug design/discovery. • Examples of linear correlations between kinetic rates and binding affinity are reported. • QSKR models based on empirical and computational molecular des... |